ASTRAZENECA PLC (AZN)
TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
📈 **POSITIVE** • Medium confidence analysis (78%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business